Rigosertib
| CAS No. | 592542-59-1 |
|---|---|
| MDL No. | MFCD09038489 |
| MF | C21H25NO8S |
| MW | 451.50 |
| InChI Key | OWBFCJROIKNMGD-BQYQJAHWSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Rigosertib is an N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine with E-configuration at the double bond. It is a non-ATP-competitive PLK1 inhibitor with an IC50 of 9 nM, exhibiting anti-cancer properties. It functions as a microtubule-destabilizing agent, EC 2.7.11.21 (polo kinase) inhibitor, apoptosis inducer, and antineoplastic agent. It is the conjugate acid of rigosertib(1-).
| CAS No. | 592542-59-1 |
|---|---|
| Product Name | Rigosertib |
Associated Conditions
neoplasm·chronic myelogenous leukemia·myelodysplastic syndrome·ovarian cancer·chronic myelomonocytic leukemia·
* The information provided here is compiled from public sources and is for reference only.
